Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Fortis Healthcare - Balance sheet improving, valuations reasonable; upgrade to Hold - Anand Rathi

Posted On: 2013-02-13 20:21:57

Results in line with estimates. Fortis Healthcare's (Fortis) revenue grew 154.5% yoy to Rs. 15.4bn, better than our expected Rs. 14.9bn. Its reported EBITDA margin declined 380bps yoy to 9.9% (versus our estimated 10.3%) on payment of service fees to Religare Health Trust (RHT). The company reported exceptional gain of Rs. 9.7bn, pertaining to gain on dilution of stake in RHT. Adjusting for this gain, the company reported net loss of Rs. 433m.

Healthy growth across segments. Strong revenue growth was largely driven by 20% increase in revenue from India hospitals business with improved EBITDA margin of 15.8%. Domestic diagnostics business (Super Religare Laboratories) grew 12% yoy with 370bps yoy improvement in EBITDA margin to 10.3% (down ~400bps qoq). International business revenue came at Rs. 8.2bn, up 6.4% qoq. EBITDA margin in international business sustained at ~13%.

Our take. We believe that inflow of cash from dilution of stake in RHT, divestment of Dental Corp. subsidiary by Mar'13 and issue of equity shares through the IPP route would help the company strengthen its balance sheet substantially by bringing down D/E level to 0.5x by FY14e. Further, the proportion of revenue from India business would move up to 70%+ from ~50% currently post divestment of Dental Corp., which would bring focus back to India. We maintain revenue estimates, but lower PAT marginally to factor in higher service fees to RHT, which could hit EBITDA. Management focus is currently on strengthening balance sheet and no M&A is expected in near future, which is a positive in our view.

The stock is currently trading at EV/EBITDA valuations of 13.5x FY14e and 10.8x FY15e. We upgrade the stock to Hold from Sell on improving balance sheet and reasonable valuations. We also raise our target price to Rs. 118 (earlier Rs. 110), based on 14x FY14e EBITDA and Rs. 21 for stake in RHT. Risks. Delay in execution of expansion projects and integration of international operations.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

TCS (TCS IN) - Revenue growth way below street expectation - Cholamandalam Securities
Infosys (INFO IN) - Result in-line with street expectation; guidance disappoints - Cholamandalam Securities
BUY Dishman Pharma - Better traction expected from CRAMS and disinfectants: AnandRathi Institutional Research
Neutral on ICICI Prudential Life Insurance Co. Ltd. IPO - Angel Broking
ICICI Prudential Life Insurance Company Ltd - IPO Note - Religare
ICICI Prudential Life Insurance Co. Ltd. - Pure play on life insurance - Geojit BNP Paribas
Fiberweb India Ltd - Set to grow at a rapid pace; initiate with BUY - BOB Capital Markets Ltd
BUY Bajaj Electricals - Growth momentum in all divisions expected in 2HFY17: AnandRathi Institutional Equity
Majesco Ltd - Well-placed to Leverage Conducive Industry Tailwinds - Reliance Securities
HCL Technologies - Event Update - Automation Focus a Key Differentiator - Reliance Securities
Aurobindo Pharma - 1QFY2017 Result Update - Angel Broking
HOLD India Cements - Subdued quarter; prices to recover: AnandRathi Institutional Research
Cement - 1QFY17 Results Review - Robust performance continues on cost benefits - Reliance Securities
NTPC 1QFY17: Result Review - In line with our expectations - Maintain BUY - Reliance Securities
KNR Constructions - 1QFY2017 Result Update - Angel Broking
BUY NRB Bearings - Margin expansion in Q1 leads to robust profitability: AnandRathi Institutional Reserach
BUY AIA Engineering - Margins likely to hold: AnandRathi Institutional Reserach
BUY Vivimed Labs - Better pharma growth, lower interest cost drive earning - Anand Rathi
Radico Khaitan - 1QFY2017 Result Update - Angel Broking
BUY KNR Constructions - Strong beginning, move toward a high-growth trajectory; AnandRathi Institutional Research
Dishman Pharmaceuticals - 1QFY2017 Result Update - Angel Broking
BUY Ahluwalia Contracts India - Steady growth intact: AnandRathi Institutional Research
BUY JK Lakshmi Cement - Strong start; growth set to endure: AnandRathi Institutional Research
Ahluwalia Contracts India Ltd - 1QFY17 Result Update - BUY - Healthy Performance Continues - Reliance Securities
Sun Pharmaceuticals - 1QFY2017 Result Update - Angel Broking
BUY MRF - Outstripping yet again: Anand Rathi Institutional Research
Bajaj Electricals - 1QFY2017 Result Update - Angel Broking
Lupin - 1QFY2017 Result Update - Angel Broking
Cadila Healthcare - 1QFY2017 Result Update - Angel Broking
BUY Jyothy Laboratories - With multiple triggers, outlook 'bright': Anand Rathi Institutional Research
IPCA Laboratories - 1QFY2017 Result Update - Angel Broking
Cipla - 1QFY2017 Result Update - Angel Broking
HCL Technologies - 1QFY2017 Result Update - Angel Broking
Tech Mahindra - 1QFY2017 Result Update - Angel Broking
Linc Pen & Plastics - 1QFY2017 Result Update - Angel Broking
Garware Wall Ropes - 1QFY2017 Result Update - Angel Broking
Union Bank of India - 1QFY17 Result Update - Better show on operating front, asset quality remains weak - Reliance Securities
Colgate Palmolive (India) - 1QFY17 Result Update - Volumes Recover but at a Cost - Reliance Securities
Views on Lupin Limited 1QFY2017 Results: Angel Broking
BUY Mangalam Cement - Stellar operational performance; AnandRathi Institutional Research
BUY Majesco - Soft quarter, profitability improving: AnandRathi Institutional Research
Views on Bank of Baroda 1QFY2017 Results: Angel Broking
BUY Aegis Logistics - Strong throughput volumes, H2 to be better: AnandRathi Institutional Research
Views on Ipca Laboratories Ltd 1QFY2017 Results: Angel Broking
Views on State Bank of India 1QFY2017 Results: Angel Broking
Views on Sun Pharmaceutical Industries Limited 1QFY2017 Results: Angel Broking
Shree Cement: 1QFY17 Result: FIRST CUT - Reliance Securities
Views on Cipla Ltd 1QFY2017 Results: Angel Broking
Views on Union Bank of India 1QFY2017 Results: Angel Broking
United Phosphorus - 1QFY2017 Result Update - Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2016